刺激性肠综合征与下尿道症状之间的关联:墨西哥人口的横截面研究
Francisco A Felix-Tellez1, María F Del Rio O Brien1, María E Ibarra Tapia1
1Hospital Civil de Guadalajara "Fray Antonio Alcalde", Guadalajara, Jalisco, Mexico.
Journal of clinical gastroenterology
|October 25, 2024
概括
刺激性肠综合征 (IBS) 经常与下泌尿道症状 (LUTS) 一起发生,严重影响患者的生活质量. 建议早期识别和转诊进行尿动力学评估,以有效管理.
科学领域:
- 胃肠道学和泌尿病学
- 肠-大脑轴研究研究
- 临床的表型化 临床的表型化
背景情况:
- 刺激性肠综合征 (IBS) 影响高达3.8%的人口,通常与其他功能障碍重叠.
- 人们已经认识到IBS和尿路症状之间的关联,但具体的临床表现尚不清楚.
- 了解这种并发症对于全面的患者护理至关重要.
研究的目的:
- 调查IBS患者尿道症状的临床表型.
- 为了确定与IBS和尿路症状的重叠相关的因素.
- 评估尿路症状对IBS患者生活质量的影响.
主要方法:
- 对428名受试者进行横截面研究,其中86名受试者患有IBS (罗马四号标准).
- 使用国际禁欲协会标准对下尿道症状 (LUTS) 的分类.
- 人口,临床和生活质量数据的后勤回归分析.
主要成果:
- 在IBS患者中观察到LUTS的高患病率 (60.5%).
- IBS与LUTS (OR:2.49) 显著相关,特别是储存症状 (OR:1.94).
- 与没有 (76.7±21.8) 的患者相比,尿路症状的患者报告生活质量明显降低 (50.8±17.2).
结论:
- 下尿道症状在IBS患者中很常见,并显著降低了生活质量.
- 临床医生应考虑在IBS患者中使用LUTS,并将其转介给泌尿动力学评估.
- 针对这种重叠状况,需要有针对性的管理策略.
相关概念视频
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
145
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
145
Irritable Bowel Syndrome I: Introduction
252
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
252
Irritable Bowel Syndrome III: Medical and Nursing Management
173
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
173
Drugs for Treatment of Diarrhea-Predominant IBS
149
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
149
Chronic Bowel Disorders: Introduction
394
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
394
Drugs for Treatment of Constipation-Predominant IBS
139
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
139


